{"groups":[{"description":"Combination of cabozantinib, carfilzomib and dexamethasone\n\nCabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.\n\nCabozantinib:\n\nPhase I: Level -1 = 20 mg\n\nCarfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16\n\nDexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)","id":"FG000","title":"Level -1 = 20 mg"},{"description":"Combination of cabozantinib, carfilzomib and dexamethasone\n\nCabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.\n\nCabozantinib:\n\nPhase I: Level 0 = 40 mg\n\nCarfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16\n\nDexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)","id":"FG001","title":"Level 0 = 40 mg"},{"description":"Combination of cabozantinib, carfilzomib and dexamethasone\n\nCabozantinib: patients will receive cabozantinib orally once daily continuously during the four weeks of a 28-day cycle.\n\nCabozantinib:\n\nPhase I: Level +1 = 60 mg\n\nCarfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16\n\nDexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)","id":"FG002","title":"Level +1 = 60 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"screen failures"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"The study was terminated prior to starting the Phase II portion of the study."}